EP1407042A4 - Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids - Google Patents

Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Info

Publication number
EP1407042A4
EP1407042A4 EP02744311A EP02744311A EP1407042A4 EP 1407042 A4 EP1407042 A4 EP 1407042A4 EP 02744311 A EP02744311 A EP 02744311A EP 02744311 A EP02744311 A EP 02744311A EP 1407042 A4 EP1407042 A4 EP 1407042A4
Authority
EP
European Patent Office
Prior art keywords
hiv
treatment
aids
methods
protease inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02744311A
Other languages
German (de)
French (fr)
Other versions
EP1407042A2 (en
Inventor
Neil T Parkin
Rainer A Zeirmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monogram Biosciences Inc
Original Assignee
Virologic Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/874,472 external-priority patent/US20030108857A1/en
Priority claimed from PCT/US2002/001682 external-priority patent/WO2002068618A1/en
Application filed by Virologic Inc filed Critical Virologic Inc
Publication of EP1407042A2 publication Critical patent/EP1407042A2/en
Publication of EP1407042A4 publication Critical patent/EP1407042A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

This invention relates to antiviral drug susceptibility and resistance tests to be used in identifying effective drug regimens for the treatment of human immunodeficiency virus (HIV) infection and acquired immunodeficiency syndrome (AIDS), particularly treatment regimens including a protease inhibitor. The invention further relates to the means and methods of monitoring the clinical progression of HIV infection and its response to antiretroviral therapy using phenotypic or genotypic susceptibility assays.
EP02744311A 2001-06-04 2002-06-04 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids Withdrawn EP1407042A4 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US874472 1992-04-13
US09/874,472 US20030108857A1 (en) 2001-06-04 2001-06-04 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
PCT/US2002/001682 WO2002068618A1 (en) 2001-01-19 2002-01-18 Methods for monitoring protease inhibitor antiretroviral therapy
WOPCT/US02/01682 2002-01-18
PCT/US2002/018684 WO2002099387A2 (en) 2001-06-04 2002-06-04 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Publications (2)

Publication Number Publication Date
EP1407042A2 EP1407042A2 (en) 2004-04-14
EP1407042A4 true EP1407042A4 (en) 2006-02-22

Family

ID=26680612

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02744311A Withdrawn EP1407042A4 (en) 2001-06-04 2002-06-04 Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Country Status (2)

Country Link
EP (1) EP1407042A4 (en)
WO (1) WO2002099387A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138231B2 (en) 2000-09-15 2006-11-21 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US6869759B1 (en) 1999-06-22 2005-03-22 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7186506B1 (en) 2000-06-12 2007-03-06 Monogram Biosciences, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV/AIDS
US7384734B2 (en) 2002-02-15 2008-06-10 Monogram Biosciences, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
CN1688719A (en) 2002-07-01 2005-10-26 瓦罗洛吉克公司 Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
WO2004003514A2 (en) 2002-07-01 2004-01-08 Virologic, Inc. Compositions and methods for determining the susceptibility of a pathogenic virus to protease inhibitors
EP1726643A1 (en) * 2005-05-27 2006-11-29 Direvo Biotech AG Method for the provision, identification and selection of proteases with altered sensitivity to activity-modulating substances
US20100136516A1 (en) * 2008-12-01 2010-06-03 454 Life Sciences Corporation System and method for detection of HIV integrase variants

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078996A1 (en) * 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078996A1 (en) * 1999-06-22 2000-12-28 Virologic, Inc. Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CONDRA J ET AL: "Genetic correlation of in vivo viral isolates to indinavir, a human immunodeficiency type 1 protease inhibitor", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 70, no. 12, December 1996 (1996-12-01), pages 8270 - 76, XP002150116, ISSN: 0022-538X *
PATICK A K ET AL: "Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, US, vol. 42, no. 10, October 1998 (1998-10-01), pages 2637 - 2644, XP002978189, ISSN: 0066-4804 *
SHAFER R W ET AL: "Human Immunodeficiency Virus Reverse Transcriptase and Protease Sequence Database", NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 27, no. 1, 1 January 1999 (1999-01-01), pages 348 - 352, XP002202303, ISSN: 0305-1048 *
TEBAS PABLO ET AL: "Virologic responses to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir", AIDS (HAGERSTOWN), vol. 13, no. 2, 4 February 1999 (1999-02-04), pages F23 - F28, XP002327593, ISSN: 0269-9370 *
TISDALE MARGARET ET AL: "Resistance to the HIV protease inhibitor amprenavir in vitro and in clinical studies: A review", CLINICAL DRUG INVESTIGATION, vol. 20, no. 4, October 2000 (2000-10-01), pages 267 - 285, XP008046792, ISSN: 1173-2563 *

Also Published As

Publication number Publication date
EP1407042A2 (en) 2004-04-14
WO2002099387A2 (en) 2002-12-12
WO2002099387A3 (en) 2003-04-24

Similar Documents

Publication Publication Date Title
HUP0400685A2 (en) Modified vaccinia ankara virus variant
WO2002022076A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE508635T1 (en) VIRUS VECTORS AND THEIR USE IN THERAPEUTIC METHODS
NO20000513L (en) Oligonucleotide Transcription Primers for Effective Detection of HIV-1 and HIV-2 and Methods of Using Them
WO2004096818A3 (en) Method and compositions for identifying anti-hiv therapeutic compounds
HUP0303917A2 (en) Combinations of sterol absorption inhibitir(s) with blood modifier(s) and their use for treating vascular conditions
BR9912209A (en) Resources and methods for monitoring nucleoside reverse transcriptase inhibitor antiretroviral therapy and guide therapeutic decisions in the treatment of HIV / AIDS
BR0011939A (en) Resources and methods for monitoring protease-inhibiting antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV / AIDS
AR045870A1 (en) COMBINATION THERAPY FOR HEPATITIS C VIRUS INFECTION
BR0011555A (en) Mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance
WO2002099387A3 (en) Means and methods for monitoring protease inhibitor antiretroviral therapy and guiding therapeutic decisions in the treatment of hiv/aids
ATE356994T1 (en) SCREENING METHOD WITH PIM1-KINASE OR PIM3-KINASE
BR9911600A (en) Resources and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy
WO2005089231A3 (en) Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
WO2005027855A3 (en) Methods for treatment of hiv or malaria using combinations of chloroquine and protease inhibitors
PT1360187E (en) 3,7-DIAZABICYCOL (3.3.0) OCTANS AND ITS USE IN THE TREATMENT OF CARDIAC ARRHYTHMIAS
HUP0302233A2 (en) Methods of treating viral diseases with il-18 and il-18 combinations
DE60127331D1 (en) Gauge for aligning apertures with photocouplers and buttons, and assembly methods with use thereof
HUP0105070A2 (en) Novel treatment
EP1283272A3 (en) Methods and means for assessing HIV envelope inhibitor therapy
ATA7902002A (en) VEIN STRIPPER
WO2002022781A3 (en) Non-nucleoside reverse transcriptase inhibitor as antiretroviral therapy
NO20000514L (en) Oligonucleotide Primers for Effective Multiplex Detection of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) and Methods of Using Them
WO2005076892A3 (en) Method for determining reduced susceptibility of hiv to protease inhibitor treatment
BR0111575A (en) Means and methods for monitoring antiretroviral therapy and guiding therapeutic decisions in the treatment of HIV / AIDS

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040115

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

R17P Request for examination filed (corrected)

Effective date: 20040102

RIC1 Information provided on ipc code assigned before grant

Ipc: 7C 12Q 1/18 A

Ipc: 7G 01N 33/569 B

Ipc: 7C 12Q 1/68 B

Ipc: 7C 12Q 1/70 B

A4 Supplementary search report drawn up and despatched

Effective date: 20060104

17Q First examination report despatched

Effective date: 20060703

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONOGRAM BIOSCIENCES, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070116